The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer

Urology

Volumn 75, Issue 3, 2010, Pages 623-629

  Sartor, Oliver ^a   McLeod, David G ^b   Halabi, Susan ^c   Schellhammer, Paul F ^d   Scardino, Peter T ^e   D'Amico, Anthony V ^f   Bennett, Charles ^g   Wei, John T ^h  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e Memorial Sloan Kettering ^*  (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGISTRY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CRYOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; ORCHIECTOMY; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; SALVAGE THERAPY; TREATMENT FAILURE; UNITED STATES;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; TREATMENT FAILURE; UNITED STATES;

EID: 77649189755     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.04.059     Document Type: Article

References (15)

1. Jemel A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Stanford J., Stephenson R., Coyle L., et al. Prostate Cancer Trends, 1973-95 (1999), SEER Program, National Cancer Institute, Bethesda, MD
3. National Cancer Institute. SEER Program: SEER stage distribution by race for prostate cancer (1973-2003 varying) (2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Bethesda, MD
4. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
5. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
6. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008) 2760-2769
7. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
8. Davis T.C., Long S.W., Jackson R.H., et al. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Fam Med 25 (1993) 391-395
9. Roth A.J., Rosenfeld B., Kornblith A.B., et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer 97 (2003) 2910-2918
10. Potosky A.L., Harlan L.C., Stanford J.L., et al. Prostate cancer practice patterns and quality of life: the prostate cancer outcomes study. J Natl Cancer Inst 91 (1999) 1719-1724
11. Lubeck D.P., Litwin M.S., Henning J.M., et al., CaPSURE Research Panel. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Cancer of the prostate strategic Urologic research endeavor. Urology 48 (1996) 773-777
12. Freedland S.J., Amling C.L., Dorey F., et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60 (2002) 670-674
13. Grossfeld G.D., Stier D.M., Flanders S.C., et al. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 160 (1998) 1398-1404
14. Grossfeld G.D., Li Y.P., Lubeck D.P., et al. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 168 (2002) 530-535
15. Mehta S.S., Lubeck D.P., Sadetsky N., et al. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 171 (2004) 215-219